Ocular Therapeutix Shares Slide 8.6% as PPI Surges, Analysts Maintain Moderate Buy
Ocular Therapeutix’s shares plunged 8.6% after January’s Producer Price Index rose 0.5% (core up 0.8%), stoking inflation concerns over potential interest rate hikes. A panel of 14 analysts assigns a consensus Moderate Buy rating with 12 buys, one hold and one sell.
1. Inflation-Driven Share Decline
Ocular Therapeutix’s shares fell 8.6% in one session after wholesale inflation data showed the Producer Price Index rose 0.5% in January (vs. 0.3% forecast) and core PPI climbed 0.8% (vs. 0.3%), raising concerns about persistent price pressures and potential rate hikes.
2. Analyst Consensus Rating Details
A panel of 14 analysts assigns Ocular Therapeutix a Moderate Buy consensus, with 12 recommending buy, one hold and one sell, reflecting mixed sentiment on the ophthalmology biopharmaceutical developer’s near-term growth prospects.
3. Historical Volatility and Outlook
Ocular Therapeutix has experienced 47 moves greater than 5% over the past year and is down 25.2% year-to-date, trading 45.1% below its 52-week high; this pronounced volatility often prompts speculation on whether current levels present attractive entry points.